Axogen, Inc. reported first‑quarter 2026 revenue of $61.5 million, up 26.6% from $48.6 million in the same period a year earlier. The company posted a net loss of $19.6 million, a widening of the GAAP loss compared with the $3.8 million loss reported in Q1 2025, but the adjusted earnings per share of $0.07 matched the consensus estimate of $0.07, reflecting disciplined cost management amid a higher mix of the biologic Avance product.
Continue reading for full analysis...